<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343248</url>
  </required_header>
  <id_info>
    <org_study_id>RM08-3006</org_study_id>
    <nct_id>NCT04343248</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19&#xD;
      and other VRIs in elderly LTCF residents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and&#xD;
      safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF&#xD;
      residents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic laboratory-confirmed COVID-19</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic laboratory-confirmed VRI</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>COVID-19</condition>
  <condition>Viral Respiratory Illnesses</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo tablets orally twice daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide 600 mg administered orally twice daily for six weeks</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>NTZ (nitazoxanide)</other_name>
    <other_name>NT-300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally twice daily for six weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin Super B-Complex</intervention_name>
    <description>Vitamin Super B-Complex administered orally twice daily to maintain the blind</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female residents of LTCFs at least 55 years of age.&#xD;
&#xD;
          -  Willing and able to provide written informed consent and comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
          -  At least one symptomatic laboratory-confirmed COVID-19 illness identified among&#xD;
             residents or staff of the LTCF within 10 days prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alzheimer's disease, dementia, or other mental incapacity which precludes&#xD;
             comprehension of the study requirements or symptom diary.&#xD;
&#xD;
          -  Subjects expected to require hospitalization within the 8-week treatment and follow-up&#xD;
             period.&#xD;
&#xD;
          -  Subjects with a history of COVID-19 or known to have developed anti-SARS- CoV-2&#xD;
             antibodies.&#xD;
&#xD;
          -  Subjects who experienced a previous episode of acute upper respiratory tract&#xD;
             infection, otitis, bronchitis or sinusitis or received antibiotics for these&#xD;
             conditions or antiviral therapy for influenza within two weeks prior to and including&#xD;
             study day 1.&#xD;
&#xD;
          -  Receipt of any dose of NTZ within 7 days prior to screening.&#xD;
&#xD;
          -  Treatment with any investigational drug or vaccine within 30 days prior to screening&#xD;
             or unwilling to avoid them during the course of the study.&#xD;
&#xD;
          -  Known sensitivity to NTZ or any of the excipients comprising the study medication.&#xD;
&#xD;
          -  Subjects unable to swallow oral tablets or capsules.&#xD;
&#xD;
          -  Subjects taking medications considered to be major CYP2C8 substrates.&#xD;
&#xD;
          -  Subjects who, in the judgment of the Investigator, will be unlikely to comply with the&#xD;
             requirements of this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Bardin, PharmD, BCPS</last_name>
    <phone>813-282-8544</phone>
    <email>matthew.bardin@romark.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chappel Group Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Specialists, Inc.</name>
      <address>
        <city>Acworth</city>
        <state>Georgia</state>
        <zip>30101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Viral Respiratory Illnesses</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

